Strategic Cooperation Agreement Between Denagene Tajhiz and Door Andishan Rouhan to Expand Genetic Kit Production
New Investment to Strengthen Domestic Manufacturing, Reduce Import Dependency, and Advance Molecular Diagnostic Technologies
In line with strengthening domestic production of specialized genetic kits and enhancing the technological capacity of Iran’s laboratory and biotechnology industry, Denagene Tajhiz and Door Andishan Rouhan have signed a strategic Memorandum of Understanding (MoU). Under this agreement, the two companies will pursue targeted joint investment to develop production infrastructure, research and development (R&D), quality control systems, and standardized manufacturing processes for molecular diagnostic products.Beyond internal capacity building, this cooperation marks the entry of new investment into Iran’s genetic kit manufacturing sector, including foreign capital attracted by Denagene Tajhiz. This development is expected to play a decisive role in improving product quality, increasing production scale, expanding exports, and significantly reducing the country’s reliance on imported molecular diagnostic kits.
Advancing Product Development and Completing the Domestic Production Value Chain
Over recent years, Denagene Tajhiz has emerged as one of the active designers and manufacturers of laboratory equipment, establishing strong infrastructure in biochemistry, biology, and cellular–molecular technologies. As part of its long-term development strategy, the company has defined the local production of genetic kits as the next critical step toward completing its domestic value chain.
The cooperation agreement with Door Andishan Rouhan enables the realization of this strategic goal by facilitating capital injection, technical knowledge synergy, accelerated R&D processes, and the industrial-scale expansion of production lines.
At the same time, Denagene Tajhiz’s success in attracting foreign investment represents a major milestone, reflecting growing international confidence in the scientific and industrial capabilities of Iranian biotechnology enterprises.
Key Provisions of the Agreement: From Investment to Technology Development
Joint Investment in Genetic Kit Production Lines
Both companies have agreed to jointly finance the acquisition of advanced equipment, procurement of specialized raw materials, expansion of quality control laboratories, and development of standardized packaging infrastructure. This investment will directly contribute to higher production capacity, improved product quality, and lower final costs of genetic kits.
Utilization of Foreign Investment Attracted by Denagene Tajhiz
A key highlight of the cooperation is the allocation of foreign investment secured by Denagene Tajhiz to the development of genetic kit manufacturing. This capital enables access to modern technologies, advanced equipment, and international best practices in production and quality assurance. The entry of foreign investment into this specialized segment is considered a rare and strategic development for Iran’s laboratory equipment industry.
Expansion of Research and Development (R&D) Capabilities
The MoU places strong emphasis on strengthening Denagene Tajhiz’s R&D unit with the support of Door Andishan Rouhan. The objective is to design next-generation research and diagnostic genetic kits, enhance product accuracy and sensitivity, and ensure full compliance with international standards.
Establishment of a Joint Steering and Monitoring Committee
To ensure effective implementation, a joint committee will be formed to oversee all stages of the project, including design, manufacturing, quality control, raw material supply, and market development.
Reducing Dependence on Imports: A Strategic National Objective
Currently, a significant portion of genetic kits and consumables used in molecular diagnostics are imported, leading to higher costs, supply chain vulnerabilities, and market volatility. The establishment and expansion of domestic genetic kit production lines under this agreement will gradually reduce dependency on imports, improve supply stability, and enable faster response to the needs of laboratories and healthcare centers. This initiative is particularly critical under international sanctions and global supply constraints, making it a strategic step toward biosafety, healthcare security, and national resilience.
Enhancing Technical Knowledge and Molecular Diagnostic Technologies
The cooperation between Denagene Tajhiz and Door Andishan Rouhan creates a solid platform for advancing technical expertise and molecular diagnostic technologies. By strengthening laboratory infrastructure, expanding R&D activities, and leveraging international experience, the partnership enables the development of high-precision, high-sensitivity, and more stable genetic kits. Beyond technological upgrades, this process facilitates knowledge transfer, standard adoption, and practical expertise localization, laying the foundation for sustainable development of advanced biotech products.
Boosting Specialized Employment and Human Capital Development
The expansion of production lines and research units requires skilled professionals in genetics, biotechnology, molecular biology, analytical chemistry, quality control, and production management. This project is expected to generate long-term, specialized employment opportunities, helping reduce brain drain while strengthening Iran’s scientific and industrial workforce.
Export Market Expansion and Increased Global Competitiveness
By improving quality, standardizing manufacturing processes, and aligning products with international regulatory requirements, domestically produced genetic kits will gain access to regional and international markets.
Many neighboring countries face limited access to high-quality molecular diagnostic kits, creating strong export opportunities for Iranian brands. Export growth will not only generate foreign currency revenues but also enhance Iran’s position as a reliable regional supplier of molecular diagnostic technologies.
Developing a National Scientific and Industrial Ecosystem
This agreement goes beyond a conventional commercial contract. It represents the foundation for building an integrated scientific and industrial ecosystem in genetics and laboratory technologies. The synergy between capital, expertise, research infrastructure, production capacity, and distribution networks will drive continuous innovation and long-term biotech advancement.
Executive Perspectives
The CEO of Denagene Tajhiz stated:
“The development of genetic kit manufacturing has been one of our strategic priorities. Signing this agreement marks a serious new phase in our scientific and industrial growth. Beyond financial resources, this partnership enables us to adopt global standards and compete with leading international brands.”
He added:
“Our goal is to position Iran as a capable regional producer of biotechnology and molecular diagnostic equipment.”
The CEO of Door Andishan Rouhan described the cooperation as a strategic opportunity, stating:
“Denagene Tajhiz possesses strong scientific and technological infrastructure. Combining this capability with Door Andishan Rouhan’s investment capacity, managerial experience, and business networks can create a transformative impact on Iran’s genetic kit manufacturing industry. This is not merely a commercial partnership, but a national step toward strengthening domestic production and indigenous knowledge.”
Future Outlook
According to the joint roadmap:
• Phase One will focus on establishing and expanding production and laboratory infrastructure.
• Phase Two will involve large-scale manufacturing of specialized genetic kits.
• Phase Three will prioritize export development and entry into regional and global markets.
Conclusion
The cooperation agreement between Denagene Tajhiz and Door Andishan Rouhan marks the beginning of a structured and strategic movement toward domestic genetic kit production. By combining domestic and foreign investment, expanding R&D infrastructure, strengthening production lines, and standardizing products, this partnership has the potential to position Iran as a key regional player in molecular diagnostics. This initiative represents not only an industrial milestone, but also a significant step toward scientific self-reliance, improved public health, and advanced biotechnology development.
